ASTRAZENECA's experimental COVID-19 vaccine was safe and produced an immune response in early-stage clinical trials in healthy volunteers, data has shown, with the strongest response seen in people who received two doses. The vaccine, called AZD1222 and being developed by AstraZeneca and scientists at Britain's University of Oxford, did not prompt any serious side effects and elicited antibody and T-cell immune responses, according to trial results published in The Lancet medical journal. "There is still much work to be done before we can confirm if our vaccine will help manage the COVID-19 pandemic, but these early results hold promise," vaccine…